After a headline-grabbing breast implant scandal rocked the continent, EU regulators are considering a more stringent approach to medical device regulation, a proposal industry leaders say would hamstring Europe's successful medical device sector.
The long and colorful Poly Implant Prothèse saga is slowly drawing to a close, as prosecutors are asking for a four-year jail sentence and $128,000 fine for the CEO who presided over the sale of faulty breast implants to thousands of women.
The Poly Implant Prothèse scandal left more than 400,00 women with toxic breast implants and sparked medical device regulatory reforms across the EU, and now 5 of the company's former execs are enduring boos and hisses from wronged patients as their trial gets under way in France.
In a world in which drugmakers must meet a growing diversity of formulation demands, capsule manufacturer Capsugel has won an organic certification for a plant in France that is focused on Europe, considered the largest market for organic products.
Switzerland, home to such Big Pharma players as Roche and Novartis, has been given a pass from some of the reporting requirements of the European Union's new API rules meant to keep counterfeit drugs out.
The EU is looking to liberalize its clinical trial regulations to spur drug development in the Continent, and the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) wants to hear from CROs and drugmakers on the proposed reforms.
After the continental fallout that ensued from Europe's faulty breast implant scandal, the EU is looking to tighten up its medical device regulations to avoid a repeat scandal.
Starting in January, all active pharmaceutical ingredients shipped into the EU must meet good manufacturing practice standards, and by July, they'll also need documented certification from their countries of origin.
The European Union appears to be moving ahead with rules that next year active pharmaceutical ingredients (APIs) exported to EU countries must be certified by some authority in the country from which the originate.
Regulators in the EU gave their blessing Friday to the $5.53 billion buyout of Swiss drugmaker Actavis by Watson Pharmaceuticals ($WPI), Reuters reports.